603439.SH
三力制药
SSE · Healthcare · Biotechnology · CN
CNY 12.12
−2.34%Year over year
Reported trailing growth
- Revenue
- -21.4%
- EBITDA
- —
- EBIT
- -77.4%
- EPS
- -80.8%
- Free cash flow
- +269.5%
- Operating cash flow
- +125.0%
Forward estimates
Based on analyst estimates
- Revenue
- -51.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +12.3%
- EBITDA
- -17.3%
- EBIT
- -34.1%
- Net income
- -38.7%
- EPS
- -39.2%
- Free cash flow
- -7.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026